Estimates Revisions Avalo Therapeutics, Inc.
Stocks
AVTX
US05338F3064
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
16:00:00 2026-10-02 EDT
|
5-day change | 1st Jan Change | ||
| 14.99 USD | +0.27% |
|
-3.10% | -17.46% |
| 09-20 | Avalo Therapeutics, Inc.(NasdaqCM:AVTX) added to S&P Global BMI Index | CI |
| 08-19 | Avalo Therapeutics Insider Sold Shares Worth $1,450,419, According to a Recent SEC Filing | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
Dividend / Share (DPS) - Evolution of Analysts' Estimates
Cash or Net Debt - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | - | - | ||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
Dividend / Share (DPS)
Cash or Net Debt
- Stock Market
- Stocks
- AVTX Stock
- Consensus Avalo Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
